Arvinas Inc (ARVN) Stock Forecast & Price Target

Arvinas is positioned for a potentially important inflection as 3Q26 sets up a series of readouts beginning with ARV-393 later this year, which could shift the story from platform promise to measurable clinical differentiation in lymphoma. The company’s outlook is strengthened by a broad pipeline spanning oncology and neurology, including ARV-027, ARV-102, ARV-6723, and vepdegestrant, while management highlighted activity across seven checkpoint-resistant preclinical models and a European-led path for ARV-102 despite the U.S. clinical hold. Even with a lower valuation framework, the revised view still favors the stock because upcoming data could validate target engagement, response depth, and tolerability, with mid-2027 updates and the potential partner-dependent ARV-806 program adding further optionality.

Arvinas is facing a weaker fundamental outlook because management has pushed expected launch timelines out across the pipeline, which delays cash flows and lowers their present value while leaving the company reliant on a still early-stage development platform. The decision to seek an out-licensing agreement for additional ARV-806 trials signals capital constraints and reprioritization after only immature early activity and tolerability data, which raises execution risk for a program that must compete in crowded oncology markets. With clinical, regulatory, competitive, and financing risks all elevated, the company may need additional equity funding to advance its candidates, further pressuring shareholder value.